Initiation of anti-TNF therapy and the risk of optic neuritis: From the safety assessment of biologic ThERapy (SABER) study

American Journal of Ophthalmology

Volumn 155, Issue 1, 2013, Pages 183-189.e1

  Winthrop, Kevin L ^a   Chen, Lang ^b   Fraunfelder, Frederick W ^a   Ku, Jennifer H ^a   Varley, Cara D ^a   Suhler, Eric ^a   Hills, William L ^a   Gattey, Devin ^a   Baddley, John W ^b   Liu, Liyan ^c   Grijalva, Carlos G ^d   Delzell, Elizabeth ^b   Beukelman, Timothy ^b   Patkar, Nivedita M ^b   Xie, Fenglong ^b   Herrinton, Lisa J ^c   Fraunfelder, Fritz T ^a   Saag, Kenneth G ^b   Lewis, James D ^e   Solomon, Daniel H ^f   Curtis, Jeffrey R ^b   more..

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c KAISER PERMANENTE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ADULT; AGED; ALGORITHM; ANKYLOSING SPONDYLITIS; ARTICLE; CHILD; COHORT ANALYSIS; DRUG EXPOSURE; ENTERITIS; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OPTIC NEURITIS; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCHOOL CHILD; SENSITIVITY ANALYSIS; VALIDATION PROCESS;

EID: 84871241925     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2012.06.023     Document Type: Article

References (10)

1. M. Rodriguez, A. Siva, S.A. Cross, P.C. O'Brien, and L.T. Kurland Optic neuritis: A population-based study in Olmsted County, Minnesota Neurology 45 2 1995 244 250
2. I. Simsek, H. Erdem, S. Pay, G. Sobaci, and A. Dinc Optic neuritis occurring with anti-tumour necrosis factor alpha therapy Ann Rheum Dis 66 9 2007 1255 1258
3. F.W. Fraunfelder, and F.T. Fraunfelder Adverse ocular drug reactions recently identified by the national registry of drug-induced ocular side effects Ophthalmology 111 7 2004 1275 1279
4. D.H. Solomon, E. Massarotti, R. Garg, J. Liu, C. Canning, and S. Schneeweiss Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis JAMA 305 24 2011 2525 2531
5. G. Schmajuk, A.N. Trivedi, and D.H. Solomon Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans JAMA 305 5 2011 480 486
6. W.A. Ray Evaluating medication effects outside of clinical trials: New-user designs Am J Epidemiol 158 9 2003 915 920
7. L.J. Herrinton, J.R. Curtis, and L. Chen Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems Pharmacoepidemiol Drug Saf 20 11 2011 1199 1209
8. T. Bongartz, A.J. Sutton, M.J. Sweeting, I. Buchan, E.L. Matteson, and V. Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 19 2006 2275 2285
9. M.Su. TNF neutralization in Results of a randomized, placebo-controlled multicenter study The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group Neurology 53 3 1999 457 465
10. W.H. Robinson, M.C. Genovese, and L.W. Moreland Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44 9 2001 1977 1983